Rational therapeutic approaches to progressive supranuclear palsy

Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,290 · see citing works

Mammalian MAP kinase signalling cascades

Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,118 · see citing works

American Journal of Pathology

(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,961 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Betarbet, R., Sherer, T., Mackenzie, G., Garcia-Osuna, M., Panov, A., & Greenamyre, J. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,797 · see citing works

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop*

Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · see citing works

Progressive Supranuclear Palsy

Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930 · see citing works

Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress

Yakes, F. M., & Van Houten, B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.514 · Cited by 1,854 · see citing works

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · see citing works

The glamour and gloom of glycogen synthase kinase-3

Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,522 · see citing works

N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology

MOFFETT, J., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,407 · see citing works

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Javitch, J. A., D’Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,264 · see citing works

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161 · see citing works

Oxidative stress and the pathogenesis of Parkinson's disease

Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · see citing works

Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy)

Hauw, J., Daniel, S. E., Dickson, D. W., Horoupian, D. S., Jellinger, K. A., Lantos, P. L., McKee, A. C., Tabaton, M., & Litvan, I. (1994) · Neurology · doi:10.1212/wnl.44.11.2015 · Cited by 854 · see citing works

A common inversion under selection in Europeans

Stefánsson, H., Helgason, A., Þorleifsson, G., Steinthórsdóttir, V., Másson, G., Barnard, J., Baker, A., Jónasdóttir, Á., Ingason, A., Gudnadottir, V. G., et al. (2005) · Nature Genetics · doi:10.1038/ng1508 · Cited by 830 · see citing works

Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy

Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781 · see citing works

Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain

Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757 · see citing works

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A. M., Watt, H., Kilford, L., Holton, J. L., Révész, T., & Lees, A. J. (2005) · Brain · doi:10.1093/brain/awh488 · Cited by 733 · see citing works

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650 · see citing works

Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study

Schrag, A. E., Ben‐Shlomo, Y., & Quinn, N. P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04137-9 · Cited by 640 · see citing works

A clinical rating scale for progressive supranuclear palsy

Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614 · see citing works

Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients

van Leeuwen, F. W., de Kleijn, D. P. V., van den Hurk, H., Neubauer, A., Sonnemans, M. A. F., Sluijs, J. A., Köycü, S., Ramdjielal, R. D. J., Salehi, A., Martens, G. J. M., et al. (1998) · Science · doi:10.1126/science.279.5348.242 · Cited by 561 · see citing works

Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease

Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E., Beecham, G., Wang, L.-Y., Züchner, S., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 512 · see citing works

Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders

Sas, K., Robotka, H., Toldi, J., & Vécsei, L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.033 · Cited by 465 · see citing works

Chaperones increase association of tau protein with microtubules

Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., & Xu, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242720499 · Cited by 462 · see citing works

Withdrawal of Survival Factors Results in Activation of the JNK Pathway in Neuronal Cells Leading to Fas Ligand Induction and Cell Death

Le-Niculescu, H., Bonfoco, E., Kasuya, Y., Claret, F.-X., Green, D. R., & Karin, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.751 · Cited by 460 · see citing works

Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP

Josephs, K. A., Petersen, R. C., Knopman, D. S., Boeve, B. F., Whitwell, J. L., Duffy, J. R., Parisi, J. E., & Dickson, D. W. (2006) · Neurology · doi:10.1212/01.wnl.0000191307.69661.c3 · Cited by 455 · see citing works

Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease

Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R. F., & Beal, M. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 431 · see citing works

Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.

Smith, M. A., Kutty, R. K., Richey, P. L., Yan, S. D., Stern, D., Chader, G. J., Wiggert, B. O., Petersen, R. B., & Perry, G. L. (1994) · PubMed Central · Cited by 425 · see citing works

Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration

Dickson, D. W. (1999) · Journal of Neurology · doi:10.1007/bf03161076 · Cited by 424 · see citing works

FDG PET in the differential diagnosis of parkinsonian disorders

Eckert, T., Barnes, A., DHAWAN, V. M., Frucht, S. J., Gordon, M. F., Feigin, A., & Eidelberg, D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.012 · Cited by 418 · see citing works

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · see citing works

Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype

Houlden, H., Baker, M., Morris, H. R., MacDonald, N., Pickering–Brown, S., Adamson, J., Lees, A. J., Rossor, M. N., Quinn, N. P., Kertesz, A., et al. (2001) · Neurology · doi:10.1212/wnl.56.12.1702 · Cited by 409 · see citing works

Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990

Bower, J. H., Maraganore, D. M., McDonnell, S. K., et al. (1997) · Neurology · doi:10.1212/wnl.49.5.1284 · Cited by 400 · see citing works

Genetic evidence for the involvement of τ in progressive supranuclear palsy

Conrad, C., Andreadis, A., Trojanowski, J. Q., Dickson, D. W., Kang, D. E., Chen, X., Wiederholt, W. C., Hansen, L., Masliah, E., Thal, L. J., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410222 · Cited by 388 · see citing works

Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity

Matthews, R. T., Ferrante, R. J., Klivènyi, P., Yang, L., Klein, A., Mueller, G., Kaddurah-Daouk, R. F., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 374 · see citing works

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368 · see citing works

Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry

Reynolds, C. H., Betts, J. C., Blackstock, W. P., Nebreda, Á. R., & Anderton, B. H. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741587.x · Cited by 365 · see citing works

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

Höglinger, G. U., Féger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., Ruberg, M., Oertel, W. H., & Hirsch, É. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01533.x · Cited by 331 · see citing works

Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease

Smith, P. D., Crocker, S. J., Jackson-Lewis, V. R., Jordan‐Sciutto, K. L., Hayley, S. P., Mount, M. P., O'Hare, M. J., Callaghan, S. M., Slack, R. S., Przedborski, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232515100 · Cited by 310 · see citing works

Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia

Dexter, D. T., Jenner, P. G., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320716 · Cited by 292 · see citing works

Development of tau aggregation inhibitors for alzheimer's disease

Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286 · see citing works

The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal

Daniel, S. E., de Bruin, V. M. S., & Lees, A. J. (1995) · Brain · doi:10.1093/brain/118.3.759 · Cited by 276 · see citing works

Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration

Pittman, A. M., Myers, A. J., Abou‐Sleiman, P. M., Fung, H., Kaleem, M., Marlowe, L., Duckworth, J., Leung, D. G., Williams, D. R., Kilford, L., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.031377 · Cited by 275 · see citing works

Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene

Stanford, P. M., Halliday, G. M., Brooks, W. S., Kwok, J. B. J., Storey, C. E., Creasey, H., Morris, J. G. L., Fulham, M. J., & Schofield, P. R. (2000) · Brain · doi:10.1093/brain/123.5.880 · Cited by 262 · see citing works

Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study

Caparros-Lefebvre, D., & Elbaz, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10166-6 · Cited by 256 · see citing works

Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe

Champy, P., Höglinger, G. U., Féger, J., Gleye, C., Hocquemiller, R., Laurens, A., Guérineau, V., Laprévôte, O., Medja, F., Lombès, A., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02138.x · Cited by 254 · see citing works

The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts

Myers, A., Pittman, A. M., Zhao, A. S., Rohrer, K., Kaleem, M. A., Marlowe, L., Lees, A. J., Leung, D. G., McKeith, I. G., Perry, R. H., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.018 · Cited by 254 · see citing works

The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK

Nath, U. (2001) · Brain · doi:10.1093/brain/124.7.1438 · Cited by 253 · see citing works

Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy

Williams, D. R., Holton, J. L., Strand, K. M., Révész, T., & Lees, A. J. (2007) · Movement Disorders · doi:10.1002/mds.21698 · Cited by 240 · see citing works

Phosphorylated Map Kinase (ERK1, ERK2) Expression is Associated with Early Tau Deposition in Neurones and Glial Cells, but not with Increased Nuclear DNA Vulnerability and Cell Death, in Alzheimer Disease, Pick's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration

Ferrer, I., Blanco, R., Carmona, M., Ribera, R., Goutan, E., Puig, B., Rey, M. J., Cardozo, A., Viñals, F., & Ribalta, T. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00387.x · Cited by 239 · see citing works

Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders

Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A. F., Nguyen, H.-U., DeMaggio, A. J., Brickman, C. M., Brewer, G. J., Dick, R. D., Troyer, M. D., et al. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00782-2 · Cited by 237 · see citing works

Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert

Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · see citing works

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

Corre, S. L., Klafki, H., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J. M., Eriksen, J. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602913103 · Cited by 221 · see citing works

Stress‐Activated Protein Kinase/c‐Jun N‐Terminal Kinase Phosphorylates τ Protein

Reynolds, C. H., Utton, M. A., Gibb, G., Yates, A., & Anderton, B. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68041736.x · Cited by 214 · see citing works

Targeting RNA with Small Molecules

Tor, Y. (2003) · ChemBioChem · doi:10.1002/cbic.200300680 · Cited by 214 · see citing works

Annonacin, a Natural Mitochondrial Complex I Inhibitor, Causes Tau Pathology in Cultured Neurons

Escobar-Khondiker, M., Höllerhage, M., Muriel, M., Champy, P., Bach, A., Depienne, C., Respondek, G., Yamada, E. S., Lannuzel, A., Yagi, T., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1644-07.2007 · Cited by 212 · see citing works

Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies

Ferrer, I., Blanco, R. E., Carmona, M., & Puig, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100016 · Cited by 207 · see citing works

Positron Emission Tomography Study in Progressive Supranuclear Palsy

Blin, J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530070035009 · Cited by 204 · see citing works

Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells

Wang, X., Perez, E., Liu, R., Yan, L., Mallet, R. T., & Yang, S. (2006) · Brain Research · doi:10.1016/j.brainres.2006.11.032 · Cited by 203 · see citing works

The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy

Höglinger, G. U., Lannuzel, A., Escobar-Khondiker, M., Michel, P. P., Duyckaerts, C. J., Féger, J., Champy, P., Prigent, A., Medja, F., Lombès, A., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03493.x · Cited by 203 · see citing works

Mitochondrial Complex I: Structural and functional aspects

Lenaz, G., Fato, R., Genova, M. L., Bergamini, C., Bianchi, C., & Biondi, A. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.007 · Cited by 202 · see citing works

Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration

Ferrer, I., Barrachina, M., & Puig, B. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0587-8 · Cited by 197 · see citing works

An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype

Poorkaj, P., Muma, N. A., Zhukareva, V. A., Cochran, E. J., Shannon, K. M., Hurtig, H. I., Koller, W. C., Bird, T. D., Trojanowski, J. Q., Lee, V. M. ‐., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10340 · Cited by 196 · see citing works

Early diagnosis of dementia: neuropsychology

Pasquier, F. (1999) · Journal of Neurology · doi:10.1007/s004150050299 · Cited by 192 · see citing works

Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia

Josephs, K. A., Boeve, B. F., Duffy, J. R., Smith, G. E., Knopman, D. S., Parisi, J. E., Petersen, R. C., & Dickson, D. W. (2005) · Neurocase · doi:10.1080/13554790590963004 · Cited by 191 · see citing works

Abnormal metabolic networks in atypical parkinsonism

Eckert, T., Tang, C., Ma, Y., Brown, N., Lin, T. P., Frucht, S. J., Feigin, A., & Eidelberg, D. (2008) · Movement Disorders · doi:10.1002/mds.21933 · Cited by 191 · see citing works

Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.

Burn, D. J., Sawle, G. V., & Brooks, D. J. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.3.278 · Cited by 185 · see citing works

Activation of the JNK/p38 Pathway Occurs in Diseases Characterized by Tau Protein Pathology and Is Related to Tau Phosphorylation But Not to Apoptosis

Atzori, C., Ghetti, B. F., Piva, R., Srinivasan, A., Zolo, P., Delisle, M. B., Mirra, S. S., & Migheli, A. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1190 · Cited by 175 · see citing works

Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q₁₀

Moon, Y., Lee, K. H., Park, J., Geum, D., & Kim, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03112.x · Cited by 174 · see citing works

Frontal presentation in progressive supranuclear palsy

Kaat, L. D., Boon, A. J. W., Kamphorst, W., Ravid, R., Duivenvoorden, H. J., & Swieten, J. C. V. (2007) · Neurology · doi:10.1212/01.wnl.0000267643.24870.26 · Cited by 174 · see citing works

Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease

Quintanilla, R. A., & Johnson, G. V. W. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.010 · Cited by 173 · see citing works

Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy‐like tauopathy

Caparros-Lefebvre, D., Sergeant, N., Lees, A. J., Camuzat, A., Daniel, S. E., Lannuzel, A., Brice, A., TOLOSA, E. S., Delacourte, A., & Duyckaerts, C. J. (2002) · Brain · doi:10.1093/brain/awf086 · Cited by 169 · see citing works

Coupling Transcription and Alternative Splicing

Kornblihtt, A. R. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77374-2_11 · Cited by 168 · see citing works

High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy

Rademakers, R., Melquist, S., Cruts, M., Theuns, J., Del-Favero, J., Poorkaj, P., Baker, M., Sleegers, K., Crook, R., De Pooter, T., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi361 · Cited by 164 · see citing works

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 161 · see citing works

Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism

Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158 · see citing works

Linkage Disequilibrium and Association of MAPT H1 in Parkinson Disease

Skipper, L. M., Wilkes, K. M., Toft, M., Baker, M., Lincoln, S., Hulihan, M., Ross, O. A., Hutton, M., Aasly, J. O., & Farrer, M. J. (2004) · The American Journal of Human Genetics · doi:10.1086/424492 · Cited by 158 · see citing works

Acetogenins from annonaceae, inhibitors of mitochondrial complex I

Zafra-Polo, M. C., González, M. C., Estornell, E., Şahpaz, S., & Cortés, D. (1996) · Phytochemistry · doi:10.1016/0031-9422(95)00836-5 · Cited by 156 · see citing works

Short‐term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo‐controlled trial

Stamelou, M., Reuß, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade‐Brittinger, C., Oertel, W. H., et al. (2008) · Movement Disorders · doi:10.1002/mds.22023 · Cited by 150 · see citing works

Progressive supranuclear palsy: where are we now?

Burn, D. J., & Lees, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00161-8 · Cited by 137 · see citing works

A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication

Divinski, I., Mittelman, L. A., & Gozes, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403197200 · Cited by 136 · see citing works

Haplotype-specific expression of exon 10 at the human MAPT locus

Caffrey, T. M., Joachim, C. L., Paracchini, S., Esiri, M. M., & Wade‐Martins, R. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl429 · Cited by 135 · see citing works

Plasma exchange in Guillain‐Barré syndrome: One‐year follow‐up

French Cooperative Group on Plasma Exchange in Guillain‐Barré Syndrome (1992) · Annals of Neurology · doi:10.1002/ana.410320115 · Cited by 134 · see citing works

Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET

Juh, R., Js, K., Moon, D.-H., et al. (2003) · European Journal of Radiology · doi:10.1016/s0720-048x(03)00214-6 · Cited by 133 · see citing works

Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome

Tsuboi, Y., Josephs, K. A., Boeve, B. F., Litvan, I., Caselli, R. J., Caviness, J. N., Uitti, R. J., Bott, A. D., & Dickson, D. W. (2005) · Movement Disorders · doi:10.1002/mds.20478 · Cited by 129 · see citing works

Tau interaction with microtubules in vivo

Samsonov, A., Yu, J.-Z., Rasenick, M., & Popov, S. V. (2004) · Journal of Cell Science · doi:10.1242/jcs.01531 · Cited by 129 · see citing works

Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress.

Lagendijk, J., Ubbink, J. B., & Vermaak, W. J. H. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37636-7 · Cited by 125 · see citing works

Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?

Lannuzel, A., Höglinger, G. U., Verhaeghe, S. T. L., Gire, L., Belson, S., Escobar-Khondiker, M., Poullain, P., Oertel, W. H., Hirsch, É. C., Dubois, B., et al. (2007) · Brain · doi:10.1093/brain/awl347 · Cited by 124 · see citing works

O3‐04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

Wischik, C. M., Bentham, P., Wischik, D., & Seng, K. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.438 · Cited by 118 · see citing works

The tau H2 haplotype is almost exclusively Caucasian in origin

Evans, E. W., Fung, H., Steele, J. C., Eerola, J., Tienari, P. J., Pittman, A. M., de Silva, R., Myers, A., Vrièze, F. W., Singleton, A., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.119 · Cited by 117 · see citing works

Stabilization of the Tau Exon 10 Stem Loop Alters Pre-mRNA Splicing

Donahue, C. P., Muratore, C., Wu, J. Y., Kosik, K. S., & Wolfe, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600143200 · Cited by 110 · see citing works

Untangling the tau gene association with neurodegenerative disorders

Pittman, A. M., Fung, H., & de Silva, R. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl190 · Cited by 110 · see citing works

Peptide neuroprotection through specific interaction with brain tubulin

Divinski, I., Holtser‐Cochav, M., Vulih, I., Steingart, R. A., & Gozes, I. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03936.x · Cited by 108 · see citing works

Frontal Lobe Dysfunction in Progressive Supranuclear Palsy

Albers, D. S., Augood, S. J., Park, L. C. H., Browne, S. E., Martin, D. M., Adamson, J. L., Hutton, M., Standaert, D. G., Vonsattel, J. P., Gibson, G. E., et al. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740878.x · Cited by 107 · see citing works

Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra

Miller, R. M., Callahan, L. M., Casaceli, C., Chen, L., Kiser, G. L., Chui, B., Kaysser-Kranich, T., Sendera, T. J., Palaniappan, C., & Federoff, H. J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4204-03.2004 · Cited by 105 · see citing works

Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy

Ahmed, Z., Josephs, K. A., Gonzalez, J., DelleDonne, A., & Dickson, D. W. (2007) · Brain · doi:10.1093/brain/awm301 · Cited by 103 · see citing works

Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies

Höllerhage, M., Matusch, A., Champy, P., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.004 · Cited by 98 · see citing works

Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)

Zheng, S., Chen, Y., Donahue, C. P., Wolfe, M. S., & Varani, G. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.03.009 · Cited by 98 · see citing works

Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy

Swerdlow, R. H., Golbe, L. I., Parks, J. K., Cassarino, D. S., Binder, D. R., Grawey, A. E., Litvan, I., Bennett, J. P., Wooten, G. F., & Parker, W. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751681.x · Cited by 95 · see citing works

Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics

Varani, L. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.3.710 · Cited by 94 · see citing works

Lipoperoxidation Is Selectively Involved in Progressive Supranuclear Palsy

Odetti, P. R., Garibaldi, S., Norese, R., Angelini, G., Marinelli, L., Valentini, S., Menini, S., Traverso, N., Zaccheo, D., Siedlak, S. L., et al. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.5.393 · Cited by 93 · see citing works

A New Mutation of the τ Gene, G303V, in Early-Onset Familial Progressive Supranuclear Palsy

Ros, R., Thobois, S., Streichenberger, N., Kopp, N., Sánchez, M. P., Pérez, M., Hoenicka, J., Ávila, J., Honnorat, J., & de Yébenes, J. G. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1444 · Cited by 92 · see citing works

Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP

Morris, H. R., Osaki, Y., Holton, J. L., Lees, A. J., Wood, N. W., Révész, T., & Quinn, N. P. (2003) · Neurology · doi:10.1212/01.wnl.0000072325.27824.a5 · Cited by 92 · see citing works

Co-Localization of Glycogen Synthase Kinase-3 with Neurofibrillary Tangles and Granulovacuolar Degeneration in Transgenic Mice

Ishizawa, T., Sahara, N., Ishiguro, K., Kersh, J. S., McGowan, E. M., Lewis, J. M., Hutton, M. L., Dickson, D. W., & Yen, S.-H. C. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63465-7 · Cited by 90 · see citing works

Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression

Hope, A. D., de Silva, R., Fischer, D. F., Hol, E. M., van Leeuwen, F. W., & Lees, A. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01844.x · Cited by 89 · see citing works

Familial progressive supranuclear palsy

de Yébenes, J. G., Sarasa, J. L., Daniel, S. E., & Lees, A. J. (1995) · Brain · doi:10.1093/brain/118.5.1095 · Cited by 89 · see citing works

Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus

Caffrey, T. M., Joachim, C., & Wade-Martins, R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.002 · Cited by 88 · see citing works

Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration

Hosaka, K., Ishii, K., Sakamoto, S., Mori, T., Sasaki, M., Hirono, N., & Mori, E. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00102-8 · Cited by 86 · see citing works

Mitochondrial Dysfunction in Neurodegenerative Diseases

Schapira, A. H. V. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9855-x · Cited by 84 · see citing works

Familial aggregation of parkinsonism in progressive supranuclear palsy

Kaat, L. D., Boon, A. J. W., Azmani, A., Kamphorst, W., Breteler, M. M. B., Anar, B., Heutink, P., & Swieten, J. C. V. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a92bcc · Cited by 81 · see citing works

Targeting RNA: new opportunities to address drugless targets

Zaman, G. J. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02624-2 · Cited by 80 · see citing works

Evidence suggesting that Homo neanderthalensis contributed the H2 MAPT haplotype to Homo sapiens

Hardy, J., Pittman, A. M., Myers, A., Gwinn, K. A., Fung, H., de Silva, R., Hutton, M. L., & Duckworth, J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330582 · Cited by 79 · see citing works

Cytosolic Abnormally Hyperphosphorylated Tau But Not Paired Helical Filaments Sequester Normal MAPs and Inhibit Microtubule Assembly

Iqbal, K., Alonso, A. D. C., & Grundke, I. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14402 · Cited by 77 · see citing works

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection

Gozes, I., & Divinski, I. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6s605 · Cited by 77 · see citing works

Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism

Abdin, A. A., & Hamouda, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.033 · Cited by 77 · see citing works

Further Evidence for Mitochondrial Dysfunction in Progressive Supranuclear Palsy

Albers, D. S., Swerdlow, R. H., Manfredi, G., Gajewski, C. D., Yang, L., Parker, W. D., & Beal, M. F. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7607 · Cited by 72 · see citing works

NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell

Gozes, I., & Divinski, I. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018208 · Cited by 71 · see citing works

Evidence for Oxidative Stress in the Subthalamic Nucleus in Progressive Supranuclear Palsy

Albers, D. S., Augood, S. J., Martin, D. M., Standaert, D. G., Vonsattel, J. P., & Beal, M. F. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730881.x · Cited by 70 · see citing works

Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms

Melquist, S., Craig, D. W., Huentelman, M. J., Crook, R., Pearson, J. V., Baker, M. C., Zismann, V., Gass, J. M., Adamson, J. L., Szelinger, S., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513320 · Cited by 70 · see citing works

Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection

Oliva, R., TOLOSA, E. S., Ezquerra, M., Molinuevo, J. L., Valldeoriola, F., Burguera, J. A., Calopa, M., Villa, M., & Ballesta, F. (1998) · Archives of Neurology · doi:10.1001/archneur.55.8.1122 · Cited by 70 · see citing works

Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease

Vandrovcová, J., Pittman, A. M., Malzer, E., Abou‐Sleiman, P. M., Lees, A. J., Wood, N. W., & de Silva, R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.019 · Cited by 67 · see citing works

Update on epidemiological aspects of progressive supranuclear palsy

Litvan, I. (2003) · Movement Disorders · doi:10.1002/mds.10562 · Cited by 64 · see citing works

Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans

Ezquerra, M., Pastor, P., Valldeoriola, F., Luis Molinuevo, J., Blesa, R., Tolosa, E., & Oliva, R. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00738-7 · Cited by 58 · see citing works

Bcl-2, Bax and Bcl-x expression following hypoxia-ischemia in the infant rat brain

Ferrer, I., Pozas, E., Serrano-López, E. M., et al. (1997) · Acta Neuropathologica · doi:10.1007/s004010050753 · Cited by 56 · see citing works

Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis

Juh, R., Pae, C., Kim, T., Lee, C., Choe, B., & Suh, T. S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.057 · Cited by 55 · see citing works

Progressive Supranuclear Palsy

Rajput, A. H., & Rajput, A. H. (2001) · Drugs & Aging · doi:10.2165/00002512-200118120-00003 · Cited by 51 · see citing works

Mitochondrial dysfunction in progressive supranuclear palsy

Albers, D. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00126-7 · Cited by 51 · see citing works

Mitoxantrone Analogues as Ligands for a Stem−Loop Structure of Tau Pre-mRNA

Liu, Y., Peacey, E., Dickson, J. R., Donahue, C. P., Zheng, S., Varani, G., & Wolfe, M. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9013407 · Cited by 51 · see citing works

Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy

de Silva, R., Weiler, M., Morris, H. R., Martin, E. R., Wood, N. W., & Lees, A. J. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02109-7 · Cited by 50 · see citing works

An extended 5′- <i>tau</i> susceptibility haplotype in progressive supranuclear palsy

Higgins, J. J., Golbe, L. I., Biase, A. D., Jankovic, J., Factor, S. A., & Adler, R. L. (2000) · Neurology · doi:10.1212/wnl.55.9.1364 · Cited by 49 · see citing works

Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1

Ros, R., Gómez‐Garre, P., Hirano, M., Tai, Y., Ampuero, I., Vidal, L., Rojo, A., Fontán, A., Vazquez, A., Fanjul, S., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20449 · Cited by 49 · see citing works

Cerebral perfusion in progressive supranuclear palsy.

Johnson, K. A., Sperling, R. A., Holman, B. L., et al. (1992) · PubMed · Cited by 49 · see citing works

A τ Promoter Region Without Neuronal Specificity

Andreadis, A., Wagner, B. K., Broderick, J. A., & Kosik, K. S. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062257.x · Cited by 47 · see citing works

In vivo Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy

Stamelou, M., Pilatus, U., Reuß, A., Magerkurth, J., Eggert, K. M., Knake, S., Ruberg, M., Schade‐Brittinger, C., Oertel, W. H., & Höglinger, G. U. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.2 · Cited by 45 · see citing works

Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography

Karbe, H., Grond, M., Huber, M., et al. (1992) · Journal of Neurology · doi:10.1007/bf00862982 · Cited by 45 · see citing works

Biochemical and Thermodynamic Characterization of Compounds That Bind to RNA Hairpin Loops: Toward an Understanding of Selectivity

Thomas, J. R., Liu, X., & Hergenrother, P. J. (2006) · Biochemistry · doi:10.1021/bi0607296 · Cited by 44 · see citing works

The Tau Gene Haplotype H1 Confers a Susceptibility to Parkinson’s Disease

Zhang, J., Song, Y., Chen, H., & Fan, D. (2004) · European Neurology · doi:10.1159/000082956 · Cited by 43 · see citing works

Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression.

Fernandez-Gomez, F. J., Pastor, M., García-Martínez, E., de Mera, R. M. D., Gou-Fàbregas, M., Gomez-Lazaro, M., Calvo, S., Soler, R., Galindo, M., & Jordán, J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.07.005 · Cited by 43 · see citing works

The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau

HARTZLER, A., ZHU, X., SIEDLAK, S., CASTELLANI, R., AVILA, J., PERRY, G., & SMITH, M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00029-5 · Cited by 43 · see citing works

Atypical parkinsonism and Annonaceae consumption in New Caledonia

Angibaud, G., Gaultier, C., & Rascol, O. (2004) · Movement Disorders · doi:10.1002/mds.20104 · Cited by 42 · see citing works

Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential

Menke, T., Gille, G., Reber, F., et al. (2003) · BioFactors · doi:10.1002/biof.5520180208 · Cited by 41 · see citing works

Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.

Dickey, C. A., Ash, P. E. A., Klosak, N., Lee, C. W., Petrucelli, L., Hutton, M. L., & Eckman, C. B. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-6 · Cited by 40 · see citing works

Expression and activity of antioxidants in the brain in progressive supranuclear palsy

Cantuti‐Castelvetri, I., Keller-McGandy, C. E., Albers, D. S., Beal, M. F., Vonsattel, J., Standaert, D. G., & Augood, S. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02244-8 · Cited by 39 · see citing works

Identification of Tau Stem Loop RNA Stabilizers

Donahue, C. P., Ni, J., Rozners, E., Glicksman, M. A., & Wolfe, M. S. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107302676 · Cited by 38 · see citing works

Mental Rotation of Perspective Stimuli in a California Sea Lion (Zalophus californianus)

Stich, K. P., Dehnhardt, G., & Mauck, B. (2003) · Brain Behavior and Evolution · doi:10.1159/000069355 · Cited by 36 · see citing works

Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene

Rossi, G., Gasparoli, E., Pasquali, C., Fede, G. D., Testa, D., Albanese, A., Bracco, F., & Tagliavini, F. (2004) · Annals of Neurology · doi:10.1002/ana.20006 · Cited by 35 · see citing works

Geographic isolates of atypical Parkinsonism and tauopathy in the tropics: Possible synergy of neurotoxins

Caparros-Lefebvre, D., Steele, J. C., Kotake, Y., et al. (2006) · Movement Disorders · doi:10.1002/mds.21024 · Cited by 34 · see citing works

Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids

Chirichigno, J. W., Manfredi, G., Beal, M. F., & Albers, D. S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03101-3 · Cited by 33 · see citing works

Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis

Caparros-Lefebvre, D., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20553 · Cited by 30 · see citing works

Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein

Fergusson, J., Landon, M., Lowe, J. S., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00917-9 · Cited by 30 · see citing works

Widespread spinal cord involvement in progressive supranuclear palsy

Iwasaki, Y., Yoshida, M., Hashizume, Y., et al. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00787.x · Cited by 28 · see citing works

5′-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration

Cruchaga, C., Vidal-Taboada, J. M., Ezquerra, M., Lorenzo, E., Martínez‐Lage, P., Estrada, M. B., TOLOSA, E. S., & Pástor, P. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.027 · Cited by 27 · see citing works

Association of the Tau haplotype with Parkinson's disease in the Greek population

Fidani, L., Kalinderi, K., Bostantjopoulou, S., Clarimón, J., Goulas, A., Katsarou, Z., Hardy, J., & Kotsis, A. (2006) · Movement Disorders · doi:10.1002/mds.20864 · Cited by 26 · see citing works

Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes.

Rango, M., Arighi, A., Biondetti, P., et al. (2007) · PubMed · Cited by 17 · see citing works

Cerebral Oxygen Metabolism in Patients with Progressive Supranuclear Palsy: A Positron Emission Tomography Study

Santens, P., Reuck, J. D., Crevits, L., et al. (2008) · European Neurology · doi:10.1159/000117398 · Cited by 17 · see citing works

Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.

van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7 · see citing works

Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans

Hope, A. D., Lashley, T., Lees, A. J., & de Silva, R. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.127 · Cited by 5 · see citing works

Untitled work

(2000) · doi:10.1002/1531-8249(200011)48:5

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · see citing works

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

PSP Genetics Study Group, Höglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M. A., Wang, L.-S., Klei, L., Rademakers, R., de Silva, R., Litvan, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.859 · Cited by 603 · see citing works

A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320 · see citing works

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · see citing works

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161 · see citing works

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis

Zhao, Y., Tseng, I.-C., Heyser, C. J., Rockenstein, E., Mante, M., Adame, A., Zheng, Q., Huang, T., Wang, X., Arslan, P. E., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.08.020 · Cited by 98 · see citing works

[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy

Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72 · see citing works

Diagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers

Benussi A, B. B. (2014) · Journal of Alzheimer's Disease &amp; Parkinsonism · doi:10.4172/2161-0460.1000168 · Cited by 6 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Depressive symptoms in progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, Huntington's disease and Creutzfeldt-Jakob disease

竹之下, 慎., 寺田, 整., Miki, T., et al. (2018) · 老年精神医学雑誌

Genetic dissection of neurodegenerative disease

Hardy, J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00013-x · Cited by 7 · see citing works

Genetics and Genomics of Parkinson's Disease

Jain, S., & Singleton, A. B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374934-5.00054-4 · Cited by 2 · see citing works